{"id":65868,"date":"2026-08-03T08:08:13","date_gmt":"2026-08-03T12:08:13","guid":{"rendered":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/tyson-foods-beats-earnings-estimates-eli-lilly-secures-fda-breakthrough-status\/65868\/"},"modified":"2026-08-03T08:08:13","modified_gmt":"2026-08-03T12:08:13","slug":"tyson-foods-beats-earnings-estimates-eli-lilly-secures-fda-breakthrough-status","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/tyson-foods-beats-earnings-estimates-eli-lilly-secures-fda-breakthrough-status\/65868\/","title":{"rendered":"Tyson Foods Beats Earnings Estimates; Eli Lilly Secures FDA Breakthrough Status"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>Tyson Foods (<a href=\"\/stock\/TSN\">TSN<\/a>)<\/strong> reported <strong>Q3 2026 adjusted EPS of $0.99<\/strong>, surpassing analyst estimates of <strong>$0.97<\/strong>, despite a slight revenue miss at <strong>$13.87 billion<\/strong>.<\/li>\n<li><strong>Eli Lilly (<a href=\"\/stock\/LLY\">LLY<\/a>)<\/strong> received <strong>FDA Breakthrough Therapy designation<\/strong> for its drug <strong>olomorasib<\/strong>, targeting a specific mutation in <strong>advanced pancreatic cancer<\/strong>.<\/li>\n<li>UK Prime Minister <strong>Andy Burnham<\/strong> is reportedly considering a fresh <strong>King\u2019s Speech<\/strong> to redefine his government&#39;s legislative priorities following his recent appointment.<\/li>\n<li>The <strong>European Commission<\/strong> has urged <strong>Spain<\/strong> to strengthen its borders following a tragic migrant surge in the enclave of <strong>Ceuta<\/strong> that resulted in at least <strong>67 deaths<\/strong>.<\/li>\n<li>Tyson Foods maintained its full-year outlook, projecting <strong>sales growth of 2.5% to 3.5%<\/strong> and adjusted operating income between <strong>$2.1 billion and $2.3 billion<\/strong>.<\/li>\n<\/ul>\n<h2>Tyson Foods Navigates Mixed Q3 Results<\/h2>\n<p>Tyson Foods (<a href=\"\/stock\/TSN\">TSN<\/a>) delivered a resilient third quarter for fiscal 2026, posting an <strong>adjusted EPS of $0.99<\/strong>, which beat the consensus estimate of <strong>$0.97<\/strong>. However, quarterly revenue of <strong>$13.87 billion<\/strong> fell short of the <strong>$14.1 billion<\/strong> anticipated by Wall Street. The company\u2019s performance was bolstered by its <strong>Chicken and Prepared Foods segments<\/strong>, which helped offset ongoing challenges in the <strong>Beef segment<\/strong> caused by a difficult cattle cycle.<\/p>\n<p>Management updated its capital expenditure guidance, now expecting <strong>$700 million to $900 million<\/strong> for the fiscal year, a tightening from the previous range of <strong>$700 million to $1 billion<\/strong>. Tyson continues to project <strong>full-year sales growth of 2.5% to 3.5%<\/strong> and expects net interest expenses to remain around <strong>$365 million<\/strong>. <em>Investors are closely monitoring the company&#39;s ability to maintain margins amidst fluctuating protein prices and operational costs.<\/em><\/p>\n<h2>Eli Lilly Gains Momentum in Oncology<\/h2>\n<p>Eli Lilly and Company (<a href=\"\/stock\/LLY\">LLY<\/a>) announced today that the <strong>U.S. FDA<\/strong> has granted <strong>Breakthrough Therapy status<\/strong> to <strong>olomorasib<\/strong> (LY3537982). This designation is specifically for the treatment of adult patients with <strong>KRAS G12C-mutant advanced pancreatic cancer<\/strong> who have previously undergone systemic therapy. This marks the second such designation for the oral inhibitor, which is also being studied for lung cancer.<\/p>\n<p>The FDA&#39;s decision was based on preliminary data from the <strong>Phase 1\/2 LOXO-RAS-20001<\/strong> study, which showed promising clinical activity in a disease area with a <strong>five-year survival rate of less than 5%<\/strong>. <em>The breakthrough status is expected to expedite the development and regulatory review process, potentially bringing a first-of-its-kind targeted therapy to pancreatic cancer patients sooner.<\/em><\/p>\n<h2>Geopolitical Shifts in the UK and EU<\/h2>\n<p>In the United Kingdom, reports from the <em>iPaper<\/em> suggest that Prime Minister <strong>Andy Burnham<\/strong> may hold a second <strong>King\u2019s Speech<\/strong> later this year. This move would allow the new administration to formalize its &quot;10-year plan&quot; and pivot legislative focus toward <strong>cost-of-living relief<\/strong> and <strong>regional devolution<\/strong>. Burnham, who recently succeeded Keir Starmer, has pledged the &quot;biggest changes in 40 years&quot; to the British economic model.<\/p>\n<p>Concurrently, European Commission President <strong>Ursula von der Leyen<\/strong> sent a formal letter to Spanish Prime Minister <strong>Pedro Sanchez<\/strong> emphasizing that the EU &quot;must do more to strengthen the borders.&quot; The communication follows a massive migration event in <strong>Ceuta<\/strong>, where approximately <strong>60,000 people<\/strong> attempted to cross from Morocco in late July. The Commission has pledged enhanced <strong>technical and financial support<\/strong> to Morocco and Spain to improve early-warning systems and border management.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways Tyson Foods (TSN) reported Q3 2026 adjusted EPS of $0.99, surpassing analyst estimates of $0.97, despite a slight [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[191,337,1807,5248,6761,14199,21031,21144],"class_list":["post-65868","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-tsn","tag-lly","tag-earnings","tag-uk-politics","tag-eli-lilly","tag-tyson-foods","tag-eu-migration","tag-pancreatic-cancer"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/65868","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=65868"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/65868\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=65868"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=65868"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=65868"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}